IL212923A0 - Methods for selecting protease resistant polypeptides - Google Patents

Methods for selecting protease resistant polypeptides

Info

Publication number
IL212923A0
IL212923A0 IL212923A IL21292311A IL212923A0 IL 212923 A0 IL212923 A0 IL 212923A0 IL 212923 A IL212923 A IL 212923A IL 21292311 A IL21292311 A IL 21292311A IL 212923 A0 IL212923 A0 IL 212923A0
Authority
IL
Israel
Prior art keywords
methods
protease resistant
resistant polypeptides
selecting protease
selecting
Prior art date
Application number
IL212923A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL212923A0 publication Critical patent/IL212923A0/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • G01N33/6857Antibody fragments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/10Libraries containing peptides or polypeptides, or derivatives thereof
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
IL212923A 2008-12-05 2011-05-16 Methods for selecting protease resistant polypeptides IL212923A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12013508P 2008-12-05 2008-12-05
PCT/EP2009/066395 WO2010063818A2 (en) 2008-12-05 2009-12-04 Methods for selecting protease resistant polypeptides

Publications (1)

Publication Number Publication Date
IL212923A0 true IL212923A0 (en) 2011-07-31

Family

ID=42169477

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212923A IL212923A0 (en) 2008-12-05 2011-05-16 Methods for selecting protease resistant polypeptides

Country Status (15)

Country Link
US (3) US8685895B2 (enExample)
EP (1) EP2364326B1 (enExample)
JP (2) JP5840498B2 (enExample)
KR (1) KR101740066B1 (enExample)
CN (1) CN102307897B (enExample)
AU (1) AU2009324037B2 (enExample)
BR (1) BRPI0922772B1 (enExample)
CA (1) CA2745448C (enExample)
EA (1) EA026508B1 (enExample)
ES (1) ES2688621T3 (enExample)
IL (1) IL212923A0 (enExample)
MX (1) MX2011005874A (enExample)
SG (1) SG194383A1 (enExample)
WO (1) WO2010063818A2 (enExample)
ZA (1) ZA201103575B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0922772B1 (pt) * 2008-12-05 2021-09-08 Glaxo Group Limited Domínio variável único de imunoglobulina e polipeptídeos isolados
US9012609B2 (en) 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
SG188204A1 (en) * 2010-08-20 2013-04-30 Glaxo Group Ltd Improved anti-serum albumin binding variants
CN104395749B (zh) * 2012-06-22 2016-12-28 奥林巴斯株式会社 含胰液成分的试样的调制方法、以及含胰液成分的生物试样的室温储存用试剂盒
RU2016104651A (ru) * 2013-07-15 2017-08-16 Норт Каролайна Стейт Юниверсити Устойчивые к протеазам пептидные лиганды
BR112016004355A2 (pt) * 2013-08-30 2017-10-17 Aprilbio Co Ltd constructo de fusão de parte efetora de fab anti-soroalbumina e método de preparação do mesmo
CN115925961A (zh) * 2015-05-28 2023-04-07 生物辐射实验室股份有限公司 亲和配体及其相关方法
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
JP6766253B2 (ja) * 2017-03-28 2020-10-07 森永乳業株式会社 新規ビフィドバクテリウム属細菌
CA3131689A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
US11584781B2 (en) * 2019-12-30 2023-02-21 Eligo Bioscience Chimeric receptor binding proteins resistant to proteolytic degradation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR20230074151A (ko) 2020-08-26 2023-05-26 트위스트 바이오사이언스 코포레이션 Glp1r 변이체에 관한 방법 및 조성물
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル. モリソン,シェリー ドメイン‐変性不変部を有する抗体
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5977307A (en) 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH06504997A (ja) 1990-12-06 1994-06-09 アフィメトリックス, インコーポレイテッド 非常に大きい規模の固定化されたポリマーの合成
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
EP1908832B1 (en) 1997-07-07 2012-12-26 Medical Research Council A method for increasing the concentration of a nucleic acid molecule
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU762814B2 (en) 1998-05-13 2003-07-03 Domantis Limited Selection system
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
GB2375112A (en) 2000-02-03 2002-11-06 Domantis Ltd Combinatorial protein domains
ATE406384T1 (de) 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー/エス 修飾glp−1の安定な処方剤
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP3299393A1 (en) 2002-11-08 2018-03-28 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
AU2004273573B2 (en) 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1737962B1 (en) 2004-03-24 2010-09-01 Domantis Limited Gas1 universal leader
WO2006059106A2 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2008062457A2 (en) * 2006-10-03 2008-05-29 Cadila Healthcare Limited Antidiabetic compounds
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA018471B1 (ru) * 2008-03-31 2013-08-30 Глаксо Груп Лимитед Слитые конструкции и конъюгаты лекарственного средства
BRPI0922772B1 (pt) * 2008-12-05 2021-09-08 Glaxo Group Limited Domínio variável único de imunoglobulina e polipeptídeos isolados
PE20120170A1 (es) * 2009-02-19 2012-03-21 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas

Also Published As

Publication number Publication date
US20140187750A1 (en) 2014-07-03
ES2688621T3 (es) 2018-11-05
CA2745448A1 (en) 2010-06-10
JP2015231380A (ja) 2015-12-24
US20110229458A1 (en) 2011-09-22
EA026508B1 (ru) 2017-04-28
WO2010063818A3 (en) 2010-08-12
US20180088128A1 (en) 2018-03-29
CN102307897B (zh) 2016-01-20
EA201170762A1 (ru) 2011-12-30
WO2010063818A2 (en) 2010-06-10
SG194383A1 (en) 2013-11-29
ZA201103575B (en) 2012-01-25
EP2364326A2 (en) 2011-09-14
CA2745448C (en) 2018-09-18
AU2009324037A1 (en) 2010-06-10
US10302655B2 (en) 2019-05-28
EP2364326B1 (en) 2018-07-04
US8685895B2 (en) 2014-04-01
US10466252B2 (en) 2019-11-05
JP2012510803A (ja) 2012-05-17
JP5840498B2 (ja) 2016-01-06
BRPI0922772A2 (en) 2018-11-06
MX2011005874A (es) 2011-06-27
KR20110102397A (ko) 2011-09-16
CN102307897A (zh) 2012-01-04
BRPI0922772B1 (pt) 2021-09-08
AU2009324037B2 (en) 2015-07-30
KR101740066B1 (ko) 2017-05-25

Similar Documents

Publication Publication Date Title
ZA201103575B (en) Methods for selecting protease resistant polypeptides
GB0721686D0 (en) Polypeptides
IL213950A0 (en) Transaminase polypeptides
ZA200810738B (en) Polypeptide
ZA201000283B (en) Reinigung pegylierter polypeptide
GB0723712D0 (en) Peptides
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB0920981D0 (en) Peptides
EP2123666A4 (en) PEPTIDE
ZA201108446B (en) FViII-DERIVED PEPTIDES
ZA201203722B (en) Peptide
GB0809659D0 (en) Polypeptides
GB0712302D0 (en) Chrondroitinase polypeptides
EP2136831A4 (en) ANTI-ANGIOGENIC PEPTIDES
GB0703945D0 (en) Peptide
GB0920987D0 (en) Peptides
GB0623539D0 (en) Polypeptides
IL197675A0 (en) Peptides
GB0817978D0 (en) Peptides
GB0804696D0 (en) Detecting polypeptides
GB0812093D0 (en) Phylloseptin peptides
GB0815673D0 (en) Peptides
GB0810449D0 (en) Peptides
GB0705115D0 (en) Peptides
GB0705251D0 (en) Peptides